Immutep (ASX:IMM) completes $12 million placement

Company News

by Rachael Jones

Biotech company Immutep (ASX:IMM) has today successfully completed a $12 million placement to professional, institutional and sophisticated investors.

Readouts from their TACTI-002 phase II trial showed an improved overall response rate of 53 per cent in 1st line lung cancer patients receiving efti as part of a combination treatment with Merck´s Keytruda.

This compares very favourably to an overall response rate of 20% for patients receiving Keytruda alone in historical trials.

The Company will use the proceeds received from the Placement to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease.

This includes the ongoing clinical development of eftilagimod alpha (“efti” or “IMP321”), the cell-line development of IMP761, R&D, manufacturing and general corporate purposes.

Shares in Immutep (ASX:IMM) are trading 2.86 per cent higher to 18 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.